Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (7651)	11/5/1998 8:24:00 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Those job postings and descriptions have not escaped my attention. Here is food for thought. Below is a link on antibiotic prophylaxis in critical care patients. About 30% die. Prophylaxis spares many from pneumonia. Of about every 23 treated, 1 less will die. Since we are in discussion of bpi as a antibiotic helper (or antibiotic itself), I thought this could be quite relevant to our trauma trial. Especially when one considers the similarities, and factors in resistance and virulence. Remember, many in the trauma trial are already receiving prophylaxis. So the trauma trial is basically prophylaxis PLUS bpi. You listening there bluegreen? VBG the link>http://www.bmj.com/cgi/content/full/316/7140/1275 All IMO